‘Strikingly better’: Co-antibody combination tops golimumab, guselkumab in refractory IBD
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.